‘She's a miracle': Toddler bit twice by rattlesnake, received more than 30 vials of antivenom
***Video above: How to survive an animal attack***
FLORENCE, Arizona (WJW) – A toddler is recovering in the hospital after she was bit twice by a rattlesnake in Arizona.
Jacquelyn Reed, who lives with her family near Florence, Arizona, said the incident happened while she was walking with her young daughter, 15-month-old Cara, outside their home late last week.
'I left her side to throw a piece of trash away 50 feet away. While I was gone for less than 10 seconds, it seems the snake got her twice,' she wrote on Facebook. 'I came back and she was crying, I saw her foot and the snake tucked behind a propane tank against our house.'
The family rushed Cara to the emergency room, where medical professionals started giving her antivenom.
'Sweet Cara was neurologically decompensating pretty quickly and began vomiting quite a lot as she was becoming lethargic,' Jacquelyn continued in the post.
Cara was intubated and flown to Phoenix Children's Hospital's pediatric intensive care unit.
'She has received quite a bit of antivenom and the team here has been more than on top of it,' the mother said over the weekend. 'They are keeping a super close eye on her foot, the blood flow and the swelling but keeping her intubated for her pain control.'
Poisonous plant rapidly spreading across Ohio: what to do if you see it
The child's aunt, Delia Reed, wrote on a GoFundMe page that Cara received more than 30 vials of antivenom during treatment.
Jacquelyn has been documenting her daughter's time in hospital after since, showing photos of Cara's with oxygen tubes and a blackened foot.
At times, Cara's oxygen levels dropped as low as 25% and doctors told the family that her foot injury is 'one of the most severe,' Jacquelyn wrote on Tuesday.
'We will be looking to see what kind of recovery she can make, but right now, nothing is off the table as far as her long term damage goes,' she said.
But the family has shared some uplifting news in recent days.
'Cara was able to come off of the heliox and progress to no oxygen at all by the end of the day!' the mother said on Thursday. 'This morning we decided to stop her tube feeds and see if we can encourage eating again. Hopefully she starts to eat enough to where we can take her home without a tube feed!'
So, what's next? According to Jacquelyn, doctors are waiting for Cara's foot to 'finish its progression' before follow-up tests to determine if the venom is still in the toddler's system, causing internal bleeding.
In the latest update, Jacquelyn thanked everyone for showing their love and support, saying 'Our sweet warrior continues to fight a hard fight and we are so cheering her on!'
'We are so blessed,' Jacquelyn told FOX 8 News on Thursday. 'Every MD who comes by to see her again says that she's a miracle. She shouldn't be here.'
FDA warns of 'rare but severe itching' after using popular allergy medications
According to the Cleveland Clinic, venomous bites, which occur when the snake injects venom into the body during a bite, are considered dangerous and often life-threatening.
If a victim is bit more than once, according to the Cleveland Clinic, they could get multiple multiple doses of venom.
'This can increase the severity of your symptoms and lessen the amount of time to get treatment to stop severe symptoms from affecting you,' the clinic said.
As of Thursday evening, the GoFundMe page has raised more than $17,000 to help the family with medical expenses.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Neuralink raises $650M to help expand patient access
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Elon Musk's Neuralink closed a $650 million funding in a Series E round, the company said Monday. The company said it plans to use the funds to expand patient access and 'innovate future devices that deepen the connection between biological and artificial intelligence.' Neuralink also announced that its brain implant has entered clinical trials in three countries, and that five people with severe paralysis are now using the implant to control digital and physical devices. Neuralink's brain computer interface consists of a chip that is surgically implanted in the skull, as well as electrodes that connect to the brain's cerebral cortex. It's designed to allow people to control a computer or mobile device. The latest fundraise included investors ARK Invest, Founders Fund, G42, Lightspeed, Sequoia Capital and others. Neuralink previously raised $280 million in a Series D round in 2023. Last year, Noland Arbaugh became the first person to receive the implant, which allowed him to move a cursor on a screen and play video games. Since then, Neuralink has sought additional applications. The company said last month it received the Food and Drug Administration's breakthrough designation to help restore communication for individuals with severe speech impairment. In Monday's announcement, Neuralink also said it had received breakthrough designation for vision restoration programs. The FDA determines breakthrough devices based on their potential for more effective treatment of life-threatening or irreversibly debilitating conditions. The designation gives manufacturers the opportunity to meet with FDA experts and have their submissions prioritized for review. Neuralink also said it has started clinical trials at the Barrow Neurological Institute in Phoenix, The Miami Project to Cure Paralysis at the University of Miami, the Cleveland Clinic Abu Dhabi and the University Health Network in Toronto. Recommended Reading Elon Musk's brain implant company raises $280M to fund clinical trials Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fast Company
3 hours ago
- Fast Company
Can healthcare go green without compromising safety?
U.S. hospitals generate nearly six million tons of waste each year, and a single patient can be responsible for more than 30 pounds a day. Much of that waste comes from the operating room (OR), which accounts for up to a third of a hospital's total output and is among the most expensive areas to manage. A large portion comes from single-use devices, packaging, and transport materials. These practices are often criticized, and not without reason. But in settings like transplantation, much of that waste is directly tied to protecting patients. I'm often asked, 'Why not make devices reusable?' or 'What about the environmental impact?' After years in the OR and working alongside transplant teams, I've asked those same questions. The answers aren't black and white, but that doesn't mean we should stop asking. Sustainability often gets reduced to packaging claims or material swaps. But the real impact lies in the systems we build around the product. That's the conversation we need to be having. Why single-use still matters Some of the industry's most criticized practices, like single-use devices, are also the least negotiable. Single-use eliminates the need for sterilization between uses, simplifies prep and cleanup, and reduces the risk of infection. The FDA permits reprocessing of certain single-use tools, but only under strict conditions. Nowhere is that margin tighter than in organ transplantation. There are no do-overs when you're handling a human organ. Transplant patients are especially vulnerable to infection due to immunosuppression, and even small lapses in sterility can lead to serious complications. Device-associated infections, from central lines, catheters, and ventilators, are among the most common and serious complications following transplant. The CDC also notes that while concerns persist about reusing single-use devices, more research is needed to define the risks. Devices that reduce infection risk and prevent complications can lead to fewer readmissions, which means fewer hospital resources used and better sustainability over time. The systems around the product Many conversations about sustainability start and stop with the product itself, whether it's recyclable, biodegradable, or made with 'green' materials. But many of the most wasteful decisions happen in how a product moves through the system that supports it. And when that system spans hospitals, suppliers, procurement teams, and legal departments, it's not built for fast change. Even when the intention is there, funding constraints, liability concerns, and the challenge of making changes across large networks often stand in the way. While a fragmented system can't solve the footprint of a single device, medical device companies still have control over how their products are moved and managed, and that's where meaningful change can start. Flying devices around the world might be fast, but it adds unnecessary emissions to an already resource-intensive process. And it's often done not because it's needed, but because it's familiar. Shifting to road transport takes more coordination, but it significantly cuts emissions and gives teams more control over when and how products arrive. What happens after delivery matters just as much. Without a plan for how products are returned, stocked, or moved, operations can shift into reaction mode. That's when waste shows up through emergency shipments, over-ordering, and unused inventory. In kidney transplant, for example, reusable machine perfusion systems have improved outcomes, but broader use has revealed logistical friction, including turnaround delays and higher discard rates. Inefficient habits tend to stay hidden until the consequences catch up. For years, private air travel has been the default in time-sensitive cases, but it comes with a steep environmental cost. At my current company, our team found that one chartered jet can emit as much carbon as manufacturing 200 single-use medical devices. With better planning, commercial flights can often meet the same clinical timelines and reduce emissions without compromising care. Sustainability has to show up in the operational decisions because if the systems around the product are wasteful, it doesn't matter how recyclable the product is. Recyclability won't negate the carbon footprint of wasteful shipping, inefficient production, or reactive inventory habits. A product isn't sustainable if it arrives on a private jet, was rushed through the supply chain, or sits unused on a shelf. Sustainability starts with better questions Healthcare won't eliminate waste entirely. But small changes matter. Reducing reliance on private air travel. Avoiding emergency shipments. Moving production closer to where products are used. None of it sounds radical. But over time, it adds up. And more often than not, it comes down to refusing to accept waste as the cost of doing business. For healthcare leaders, it's worth stepping back to examine the systems tied to a product and where a few deliberate improvements could make an impact. Not every change requires an overhaul. But the right operational shift, at the right point in the process, can reduce waste without ever touching the safety of patient care. And if enough companies commit to that kind of thinking, that's how you move an industry forward.
Newsweek
4 hours ago
- Newsweek
Churro Recall Map as Warning Issued in 13 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Camerican International is recalling boxes of their Aldi Brand Casa Mamita Churro Bites in certain states due to fears of undeclared milk. Newsweek reached out to the company via email Wednesday for comment. Why It Matters Numerous recalls have been initiated in 2025 due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that people with an allergy or sensitivity to milk run the risk of a potentially life-threatening reaction if they eat the recalled churro bites. What To Know In an FDA alert on Tuesday, the churro bites filled with chocolate hazelnut cream were sold at certain Aldi locations in Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina and Tennessee. The recalled product was packaged in a 7.05-ounce box with a lot number of 01425 and a best by date of July 14, 2025. The FDA says that there have been no reported illnesses related to this recall. Below is a map of the states impacted by the recall: What People Are Saying The FDA in the alert in part: "The recall was initiated after a consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk. Subsequent investigation indicates the problem was caused by a temporary breakdown in the company's production and packaging processes that has subsequently been corrected." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled product are urged to return it to the original place of purchase for a full refund, the FDA says. People with any additional questions may call the company at 1-201-587-0101 on weekdays from 8:30 a.m. to 5 p.m. ET.
